Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

William Elliott

Concepts (374)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Hypertension
109
2017
1218
12.500
Why?
Antihypertensive Agents
69
2017
577
11.460
Why?
Blood Pressure
54
2017
1207
4.570
Why?
Amlodipine
5
2017
42
2.470
Why?
Perindopril
4
2017
8
2.450
Why?
Calcium Channel Blockers
19
2011
234
2.160
Why?
Angiotensin-Converting Enzyme Inhibitors
20
2008
251
2.020
Why?
Atenolol
6
2014
41
1.290
Why?
Patient Compliance
9
2008
252
1.270
Why?
Diuretics
15
2008
146
1.200
Why?
Cardiovascular Diseases
12
2015
822
1.050
Why?
Adrenergic beta-Antagonists
9
2011
165
0.990
Why?
Humans
132
2017
84808
0.970
Why?
Hydrochlorothiazide
9
2012
85
0.950
Why?
Coronary Disease
7
2006
307
0.890
Why?
Practice Guidelines as Topic
9
2017
1091
0.890
Why?
Randomized Controlled Trials as Topic
14
2017
869
0.880
Why?
Verapamil
14
2007
79
0.850
Why?
Renal Insufficiency, Chronic
2
2016
304
0.840
Why?
Blood Pressure Determination
6
2016
97
0.790
Why?
Angiotensin Receptor Antagonists
6
2005
82
0.730
Why?
Chlorthalidone
3
2008
33
0.720
Why?
Blood Pressure Monitoring, Ambulatory
8
2011
84
0.710
Why?
American Heart Association
4
2015
88
0.700
Why?
Meta-Analysis as Topic
9
2017
104
0.670
Why?
Drug Therapy, Combination
13
2015
994
0.670
Why?
Life Style
3
2013
193
0.670
Why?
Diabetes Mellitus
6
2015
765
0.660
Why?
Blood Glucose
3
2012
907
0.650
Why?
Physician's Role
2
2013
187
0.640
Why?
Drug Combinations
7
2017
245
0.630
Why?
Sodium Potassium Chloride Symporter Inhibitors
1
2016
6
0.630
Why?
Disease Management
3
2013
342
0.590
Why?
United States
21
2015
6459
0.570
Why?
Diabetes Complications
2
2011
222
0.570
Why?
Adrenergic beta-1 Receptor Antagonists
1
2014
12
0.560
Why?
Metoprolol
1
2014
31
0.560
Why?
Cough
4
2017
50
0.560
Why?
Population Surveillance
2
2014
249
0.510
Why?
Kidney
5
2014
1245
0.510
Why?
Drugs, Generic
1
2013
21
0.510
Why?
Amiloride
2
2012
41
0.510
Why?
Enalapril
3
1999
21
0.500
Why?
Sodium Chloride Symporter Inhibitors
6
2005
53
0.500
Why?
Reimbursement Mechanisms
1
2013
40
0.500
Why?
Hypertension, Renovascular
2
2008
17
0.490
Why?
Specialization
1
2013
66
0.490
Why?
Treatment Outcome
20
2016
7997
0.490
Why?
Clinical Trials as Topic
11
2015
1212
0.470
Why?
Stroke
5
2012
803
0.450
Why?
Pharmacists
2
2003
26
0.450
Why?
Risk Factors
17
2015
5482
0.440
Why?
Angiotensin II Type 1 Receptor Blockers
6
2012
99
0.440
Why?
Edema
3
2017
73
0.420
Why?
Cyclooxygenase 2 Inhibitors
1
2010
34
0.420
Why?
Anti-Inflammatory Agents, Non-Steroidal
2
2010
242
0.420
Why?
Myocardial Infarction
4
2005
378
0.410
Why?
Male
55
2015
42330
0.380
Why?
Double-Blind Method
18
2015
1915
0.380
Why?
Tetrazoles
4
2002
54
0.370
Why?
Emergency Treatment
2
2006
44
0.370
Why?
Proteinuria
3
2005
114
0.370
Why?
Middle Aged
50
2015
25832
0.370
Why?
Evidence-Based Medicine
5
2017
456
0.370
Why?
Circadian Rhythm
4
2009
310
0.360
Why?
Dose-Response Relationship, Drug
10
2017
2105
0.360
Why?
Female
51
2015
45277
0.350
Why?
Nitroprusside
5
2004
40
0.350
Why?
Medication Adherence
1
2009
122
0.340
Why?
Sphygmomanometers
1
2007
3
0.340
Why?
Ear, External
3
1996
29
0.330
Why?
Prevalence
6
2015
1284
0.330
Why?
Chronotherapy
3
2001
4
0.330
Why?
Felodipine
3
2004
5
0.330
Why?
Breathing Exercises
1
2006
1
0.330
Why?
Benzothiadiazines
3
1995
21
0.320
Why?
Losartan
3
2001
46
0.320
Why?
Aged
35
2015
18700
0.320
Why?
Equipment and Supplies
1
2006
31
0.320
Why?
Public Health
1
2007
112
0.320
Why?
Heart Failure
3
2011
1128
0.310
Why?
Treatment Failure
3
2012
304
0.310
Why?
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
5
1993
9
0.310
Why?
Coronary Artery Disease
3
2015
372
0.300
Why?
Imidazoles
3
2005
169
0.300
Why?
Oncogene Proteins v-erbB
1
2005
1
0.300
Why?
Biomedical Research
1
2010
359
0.300
Why?
Interleukin-8
1
2005
86
0.290
Why?
Patient Education as Topic
3
2008
354
0.290
Why?
Prediabetic State
1
2005
44
0.290
Why?
Morpholines
1
2005
80
0.290
Why?
Indoles
3
2007
335
0.280
Why?
Vascular Endothelial Growth Factor A
2
2009
390
0.270
Why?
Valine
2
2001
78
0.270
Why?
Acrylates
2
2005
21
0.270
Why?
Thiophenes
2
2005
49
0.260
Why?
Self Administration
1
2003
79
0.260
Why?
Role
1
2003
15
0.250
Why?
Receptors, Angiotensin
2
2005
17
0.250
Why?
Cost of Illness
1
2003
154
0.230
Why?
Emergency Medical Services
1
2003
187
0.220
Why?
Health Care Costs
1
2003
226
0.220
Why?
Vasodilator Agents
4
2003
182
0.210
Why?
Drug Delivery Systems
1
2003
219
0.210
Why?
Pulse
1
2000
22
0.210
Why?
Drug Therapy
3
2000
77
0.210
Why?
Protein Kinase Inhibitors
1
2005
572
0.210
Why?
Patient Care Team
1
2003
279
0.200
Why?
Prospective Studies
8
2015
4139
0.190
Why?
Hypercholesterolemia
2
2001
240
0.180
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
2
2001
446
0.180
Why?
Dopamine Agents
4
1992
33
0.180
Why?
Cerebrovascular Disorders
2
1998
154
0.180
Why?
Pheochromocytoma
2
1989
67
0.180
Why?
Proportional Hazards Models
4
2007
879
0.180
Why?
Fenoldopam
7
2004
14
0.170
Why?
Time Factors
8
2012
5526
0.170
Why?
Pyridines
2
2010
312
0.170
Why?
Adrenal Gland Neoplasms
2
1989
101
0.170
Why?
Comorbidity
4
2015
947
0.170
Why?
Anticholesteremic Agents
1
1999
222
0.170
Why?
Professional Competence
1
2017
71
0.160
Why?
Risk Assessment
5
2015
2300
0.160
Why?
Research Report
1
2016
44
0.160
Why?
Incidence
4
2003
1659
0.160
Why?
Potassium
2
2015
309
0.150
Why?
Age Factors
7
2015
1928
0.150
Why?
Biological Availability
2
2013
105
0.150
Why?
Cost-Benefit Analysis
4
2003
420
0.150
Why?
Adult
25
2010
26295
0.150
Why?
Computer Simulation
1
2000
1066
0.140
Why?
Furosemide
2
1995
40
0.140
Why?
Hypolipidemic Agents
1
1996
123
0.140
Why?
Nifedipine
3
2001
33
0.140
Why?
Organ Transplantation
1
1998
286
0.140
Why?
Sodium
1
2016
346
0.140
Why?
Norepinephrine
3
1991
183
0.140
Why?
Single-Blind Method
3
1999
161
0.140
Why?
Heart Rate
7
2001
564
0.140
Why?
Aged, 80 and over
9
2009
6636
0.130
Why?
Risk Reduction Behavior
3
2015
109
0.130
Why?
Prognosis
5
2015
3735
0.130
Why?
Gout
1
1994
75
0.130
Why?
Cholesterol
1
1995
438
0.130
Why?
Risk
4
2010
702
0.130
Why?
Renal Artery Obstruction
1
1993
42
0.120
Why?
Disease Progression
3
2007
1487
0.120
Why?
Survival Rate
4
2015
1925
0.120
Why?
Glomerular Filtration Rate
1
2015
390
0.120
Why?
Nephrology
1
2013
42
0.120
Why?
Kidney Diseases
3
2005
425
0.120
Why?
Pulmonary Medicine
1
2013
50
0.120
Why?
Adrenergic alpha-Antagonists
2
2006
47
0.120
Why?
Clonidine
2
1991
41
0.120
Why?
Nutrition Surveys
1
2012
93
0.110
Why?
Indapamide
1
1991
4
0.110
Why?
Cardiology
1
2013
124
0.110
Why?
Cyclosporins
1
1991
66
0.110
Why?
Terminology as Topic
1
2013
219
0.110
Why?
Spain
1
2011
37
0.110
Why?
Hemodynamics
3
2015
719
0.110
Why?
Vasodilation
1
2011
99
0.110
Why?
Headache
1
2011
71
0.110
Why?
Dementia
1
2012
166
0.110
Why?
Drug Interactions
2
2006
273
0.110
Why?
Intraocular Pressure
1
1991
63
0.110
Why?
Diclofenac
1
2010
5
0.110
Why?
Asthma
2
2001
906
0.110
Why?
Dopamine
2
1990
294
0.110
Why?
Lactones
1
2010
33
0.110
Why?
Sulfones
1
2010
51
0.110
Why?
Kidney Failure, Chronic
3
2005
521
0.100
Why?
Ferricyanides
1
1990
3
0.100
Why?
Predictive Value of Tests
4
2005
1778
0.100
Why?
Cognition Disorders
1
2012
240
0.100
Why?
Isoxazoles
1
2010
79
0.100
Why?
Epidermal Growth Factor
1
2010
124
0.100
Why?
Shock
1
1990
51
0.100
Why?
Benzenesulfonates
1
2009
64
0.100
Why?
Phenoxybenzamine
1
1989
17
0.100
Why?
Biphenyl Compounds
2
2000
69
0.100
Why?
Ganglioneuroma
1
1989
13
0.100
Why?
Drug Utilization
2
2000
71
0.100
Why?
Pyrazoles
1
2010
168
0.090
Why?
Glucagon
1
1989
117
0.090
Why?
Education, Medical
1
1991
219
0.090
Why?
Prescription Fees
1
2008
11
0.090
Why?
Sulfonamides
1
2010
332
0.090
Why?
Angioplasty, Balloon
1
2008
97
0.090
Why?
Societies, Medical
3
2017
579
0.090
Why?
Chi-Square Distribution
2
2005
384
0.080
Why?
Mercury
1
2007
9
0.080
Why?
Follow-Up Studies
5
2005
3889
0.080
Why?
Journal Impact Factor
2
2017
17
0.080
Why?
Oscillometry
1
2007
34
0.080
Why?
Manometry
1
2007
44
0.080
Why?
Medical Audit
1
2007
38
0.080
Why?
Nasal Decongestants
1
2006
9
0.080
Why?
Appetite Depressants
1
2006
17
0.080
Why?
Curriculum
1
1991
493
0.080
Why?
Uric Acid
2
2001
165
0.080
Why?
Automation
1
2007
116
0.080
Why?
Costs and Cost Analysis
1
2007
153
0.080
Why?
Antineoplastic Agents
3
2010
2375
0.080
Why?
Drug Administration Schedule
2
2007
973
0.080
Why?
Severity of Illness Index
3
2015
1793
0.080
Why?
Erythropoietin
1
2006
93
0.080
Why?
Cytochrome P-450 Enzyme System
1
2006
78
0.080
Why?
Benzazepines
2
2002
93
0.080
Why?
Heart Transplantation
1
1991
674
0.080
Why?
Delayed-Action Preparations
6
2003
155
0.080
Why?
Respiratory Mechanics
1
2006
106
0.070
Why?
Magnetic Resonance Angiography
1
2008
257
0.070
Why?
Steroids
1
2006
176
0.070
Why?
Nicardipine
1
2004
7
0.070
Why?
Glucose Tolerance Test
1
2005
241
0.070
Why?
Cohort Studies
5
2015
2742
0.070
Why?
Drug Evaluation
2
2005
152
0.070
Why?
Arteries
1
2005
193
0.070
Why?
Sex Factors
4
2001
1097
0.070
Why?
Systole
3
2001
142
0.070
Why?
Recombinant Proteins
1
2006
1067
0.070
Why?
Education, Continuing
1
2003
10
0.070
Why?
Xenograft Model Antitumor Assays
1
2005
465
0.060
Why?
Administration, Oral
1
2005
729
0.060
Why?
Dosage Forms
1
2003
9
0.060
Why?
Longitudinal Studies
1
2007
996
0.060
Why?
Appointments and Schedules
1
2003
39
0.060
Why?
Chronic Disease
2
2005
982
0.060
Why?
Cost Savings
1
2003
63
0.060
Why?
Family Practice
1
2003
101
0.060
Why?
Long-Term Care
1
2003
69
0.060
Why?
Emergencies
2
2001
113
0.060
Why?
Angina Pectoris
1
2001
29
0.060
Why?
Drug Approval
1
2002
61
0.060
Why?
Interprofessional Relations
1
2003
120
0.060
Why?
United States Food and Drug Administration
1
2002
124
0.060
Why?
Sensitivity and Specificity
3
2002
2092
0.060
Why?
Brain
1
2012
2177
0.060
Why?
Signal Transduction
2
2010
3334
0.060
Why?
Quality-Adjusted Life Years
1
2002
113
0.060
Why?
Health Knowledge, Attitudes, Practice
2
2003
547
0.060
Why?
Constipation
1
2001
68
0.060
Why?
Diastole
2
1999
149
0.050
Why?
Immunosuppressive Agents
1
2006
1030
0.050
Why?
Pharmacies
1
2000
7
0.050
Why?
Pharmacokinetics
1
2000
14
0.050
Why?
Diabetic Angiopathies
1
2000
69
0.050
Why?
Pharmacology, Clinical
1
2000
10
0.050
Why?
Adolescent
6
1999
9293
0.050
Why?
Labor Unions
1
1999
1
0.050
Why?
Steel
1
1999
2
0.050
Why?
Metallurgy
1
1999
3
0.050
Why?
Indiana
1
1999
14
0.050
Why?
Animals
2
2013
27277
0.050
Why?
Managed Care Programs
1
1999
43
0.050
Why?
Models, Economic
1
1999
61
0.050
Why?
Gene Expression Regulation, Neoplastic
1
2005
1213
0.050
Why?
Benzimidazoles
1
2000
137
0.050
Why?
Drug Costs
1
2000
62
0.050
Why?
Receptors, Dopamine
2
1990
44
0.050
Why?
Retrospective Studies
3
2007
7883
0.050
Why?
Cell Line, Tumor
1
2005
2438
0.050
Why?
Sample Size
1
1999
122
0.050
Why?
RNA, Messenger
1
2005
2015
0.050
Why?
Decision Making
1
2004
626
0.050
Why?
Diabetic Nephropathies
1
2000
230
0.040
Why?
Quality Assurance, Health Care
1
1999
229
0.040
Why?
Auscultation
2
1995
7
0.040
Why?
Diltiazem
1
1996
18
0.040
Why?
Economics, Pharmaceutical
1
1996
9
0.040
Why?
Cost Control
1
1996
45
0.040
Why?
Delivery of Health Care
1
2000
327
0.040
Why?
Quality of Health Care
1
1999
370
0.040
Why?
Diet, Sodium-Restricted
1
2015
16
0.040
Why?
Quality of Life
2
2001
1394
0.040
Why?
Minoxidil
1
1995
1
0.040
Why?
Prazosin
1
1995
11
0.040
Why?
Denervation
1
2015
44
0.040
Why?
Hypertension, Renal
1
2015
43
0.040
Why?
Goals
1
2015
50
0.040
Why?
Health Expenditures
1
1996
82
0.040
Why?
Multicenter Studies as Topic
1
2015
156
0.040
Why?
Exercise Therapy
1
2015
67
0.030
Why?
Cerebral Hemorrhage
1
1998
341
0.030
Why?
Neoplasms
1
2009
2744
0.030
Why?
Arterial Occlusive Diseases
1
1995
103
0.030
Why?
Attitude of Health Personnel
1
2000
661
0.030
Why?
Bronchodilator Agents
1
1994
62
0.030
Why?
Allopurinol
1
1994
82
0.030
Why?
Kidney Function Tests
2
1993
133
0.030
Why?
Quality Improvement
1
2017
374
0.030
Why?
Captopril
1
1993
25
0.030
Why?
Obesity
1
2001
978
0.030
Why?
Drug Monitoring
1
1994
121
0.030
Why?
Brachial Artery
1
1993
40
0.030
Why?
Disease-Free Survival
1
1996
1206
0.030
Why?
Renal Insufficiency
1
1993
113
0.030
Why?
Radionuclide Imaging
1
1993
236
0.030
Why?
Renal Artery
1
1993
64
0.030
Why?
Angiotensin II
1
2012
94
0.030
Why?
Social Support
1
1994
188
0.030
Why?
Adrenal Cortex Hormones
1
1994
266
0.030
Why?
Europe
2
2002
313
0.030
Why?
Death, Sudden
1
1991
42
0.030
Why?
Executive Function
1
2012
85
0.030
Why?
Anticoagulants
1
2015
403
0.030
Why?
Epinephrine
1
1991
88
0.030
Why?
Mice
1
2005
11276
0.030
Why?
Combined Modality Therapy
1
2015
1688
0.030
Why?
Radiography
1
1993
877
0.030
Why?
Attitude
1
1991
121
0.030
Why?
Child
2
1997
6928
0.030
Why?
Hypertension, Malignant
1
1990
3
0.030
Why?
ROC Curve
1
1993
768
0.030
Why?
Body Weight
1
1991
504
0.020
Why?
Receptors, Dopamine D2
1
1990
64
0.020
Why?
Diabetes Mellitus, Type 1
1
1995
548
0.020
Why?
Niacinamide
1
2009
117
0.020
Why?
Phenylurea Compounds
1
2009
110
0.020
Why?
Electrocardiography
1
1992
597
0.020
Why?
Postoperative Complications
1
1998
2296
0.020
Why?
Safety
1
1989
174
0.020
Why?
Cognition
1
2012
513
0.020
Why?
False Positive Reactions
1
1988
227
0.020
Why?
Kidney Transplantation
2
2002
835
0.020
Why?
Monitoring, Physiologic
1
1988
286
0.020
Why?
Parathyroid Hormone
1
1988
238
0.020
Why?
Case Management
1
2006
25
0.020
Why?
Peritoneal Dialysis, Continuous Ambulatory
1
1985
18
0.020
Why?
Technology Assessment, Biomedical
1
1985
32
0.020
Why?
Creatinine
2
2000
352
0.020
Why?
Compliance
1
2005
25
0.020
Why?
Renin-Angiotensin System
1
2006
133
0.020
Why?
Drug Resistance
1
2005
267
0.020
Why?
Missouri
1
1983
30
0.020
Why?
Israel
1
1983
59
0.020
Why?
California
1
2004
142
0.020
Why?
North America
1
1983
180
0.020
Why?
Least-Squares Analysis
1
2002
56
0.020
Why?
Pilot Projects
1
2005
840
0.020
Why?
Models, Econometric
1
2002
17
0.010
Why?
Renal Dialysis
2
2002
385
0.010
Why?
Dizziness
1
2001
22
0.010
Why?
Back Pain
1
2001
37
0.010
Why?
Medicaid
1
2004
188
0.010
Why?
Markov Chains
1
2002
126
0.010
Why?
Hypertrophy, Left Ventricular
1
2001
75
0.010
Why?
Culture
1
2000
57
0.010
Why?
Reference Values
1
2000
706
0.010
Why?
Smoking
1
2003
571
0.010
Why?
Logistic Models
1
2003
1171
0.010
Why?
Statistics as Topic
1
2000
244
0.010
Why?
Survival Analysis
1
2003
1597
0.010
Why?
Pharmaceutical Preparations
1
2000
92
0.010
Why?
Monitoring, Ambulatory
1
1998
35
0.010
Why?
Chicago
1
2003
1456
0.010
Why?
Mass Screening
1
2003
652
0.010
Why?
Body Mass Index
1
2001
790
0.010
Why?
Diabetes Mellitus, Type 2
1
2006
1304
0.010
Why?
Echocardiography
1
2001
909
0.010
Why?
Analysis of Variance
1
1998
965
0.010
Why?
Propranolol
1
1994
51
0.010
Why?
Stereoisomerism
1
1994
101
0.010
Why?
Data Interpretation, Statistical
1
1996
306
0.010
Why?
Models, Biological
1
2002
1796
0.010
Why?
Guidelines as Topic
1
1994
171
0.010
Why?
Premedication
1
1991
58
0.010
Why?
Observer Variation
1
1993
622
0.010
Why?
Acute Disease
1
1992
878
0.010
Why?
Evaluation Studies as Topic
1
1988
312
0.010
Why?
England
1
1985
43
0.000
Why?
Graft Survival
1
1985
887
0.000
Why?
Graft Rejection
1
1985
1117
0.000
Why?
Elliott's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Physical Neighbors Expand Description
_